NASDAQ:BLFS - BioLife Solutions Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $50.38
Forecasted Upside: 7.89 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
2 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$46.69 As of 07/23/2021 01:00 AM ET

▲ +0.25 (0.54%)

1 month | 3 months | 12 months

Get New BioLife Solutions Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BLFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLFS

^$50.38

▲ +7.89% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $50.38, with a high forecast of $61.00 and a low forecast of $33.00. The average price target represents a 7.89% upside from the last price of $46.69.

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in BioLife Solutions. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/25/2021

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/20/2021	Benchmark	Reiterated Rating	Buy ➝ Hold		Medium
5/14/2021	Benchmark	Downgrade	Buy ➝ Hold		High
3/24/2021	B. Riley	Boost Price Target		$35.50 ➝ $61.00	Low
3/23/2021	Maxim Group	Boost Price Target	Buy	$40.00 ➝ $60.00	High
3/23/2021	Stephens	Boost Price Target	Buy ➝ Overweight	$50.00 ➝ $55.00	High
3/23/2021	KeyCorp	Boost Price Target	Overweight	$40.00 ➝ $50.00	High
3/23/2021	Benchmark	Upgrade	Hold ➝ Buy	$54.00	High
3/18/2021	B. Riley	Reiterated Rating	Buy		Low
12/28/2020	Northland Securities	Boost Price Target		$35.00 ➝ $55.00	N/A
11/9/2020	KeyCorp	Initiated Coverage	Overweight	$40.00	Low
10/19/2020	B. Riley	Boost Price Target		$30.00 ➝ $35.00	Low
9/23/2020	B. Riley	Boost Price Target		$25.50 ➝ $30.00	High
9/22/2020	Maxim Group	Boost Price Target		$26.00 ➝ $32.00	High
9/22/2020	Lake Street Capital	Boost Price Target	Buy	$29.00 ➝ $35.00	High
9/22/2020	Northland Securities	Boost Price Target	Outperform	$27.00 ➝ $35.00	Medium
9/22/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Medium
9/18/2020	Cowen	Initiated Coverage	Outperform	$33.00	High
8/11/2020	Benchmark	Downgrade	Buy ➝ Hold	$21.00	High
8/7/2020	Maxim Group	Initiated Coverage	Buy	$26.00	High
8/7/2020	Northland Securities	Reiterated Rating	Buy	$28.00	Low
7/10/2020	B. Riley	Boost Price Target	Buy	$20.00 ➝ $25.50	Low
7/8/2020	Maxim Group	Boost Price Target	Buy	$18.00 ➝ $26.00	Low
7/8/2020	Northland Securities	Reiterated Rating	Buy	$24.00 ➝ $28.00	Low
6/4/2020	HC Wainwright	Reiterated Rating	Buy	$17.00	High
5/16/2020	Maxim Group	Reiterated Rating	Buy	$18.00	High
5/15/2020	Stephens	Boost Price Target	Overweight	$23.00 ➝ $24.00	High
5/6/2020	Oppenheimer	Reiterated Rating	Buy		High
5/5/2020	HC Wainwright	Reiterated Rating	Buy	$17.00	High
5/4/2020	B. Riley	Lower Price Target	Buy	$24.00 ➝ $22.00	High
3/23/2020	HC Wainwright	Lower Price Target	Buy	$26.00 ➝ $17.00	Medium
3/12/2020	B. Riley	Lower Price Target	Buy	$27.00 ➝ $24.00	High
2/24/2020	Lake Street Capital	Initiated Coverage	Buy	$25.00	High
2/19/2020	Benchmark	Initiated Coverage	Buy	$24.00	High
2/6/2020	B. Riley	Initiated Coverage	Buy	$27.00	High
1/7/2020	Stephens	Initiated Coverage	Overweight	$23.00	High
12/16/2019	HC Wainwright	Reiterated Rating	Buy	$23.00 ➝ $26.00	Low
11/20/2019	Oppenheimer	Initiated Coverage	Outperform	$22.00	High
9/17/2019	Maxim Group	Set Price Target	Buy	$26.00	Low
9/4/2019	Northland Securities	Boost Price Target	Outperform	$18.00 ➝ $22.00	High
8/9/2019	Maxim Group	Set Price Target	Buy	$24.00	High
7/22/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$23.00	High
7/9/2019	Northland Securities	Reiterated Rating	Buy	$18.00	High
5/22/2019	Maxim Group	Set Price Target	Buy	$24.00	Low
5/13/2019	Northland Securities	Reiterated Rating	Buy	$18.00	Low
12/20/2018	Janney Montgomery Scott	Upgrade	Buy	$5.00	Low
11/9/2018	B. Riley	Set Price Target	Buy	$22.00	Low
10/3/2018	B. Riley	Set Price Target	Buy ➝ Buy	$22.00	High
9/5/2018	Maxim Group	Reiterated Rating	Buy	$26.00	High
8/14/2018	B. Riley	Set Price Target	Buy	$23.00	Low
8/10/2018	Northland Securities	Reiterated Rating	Buy	$18.00	Low
7/3/2018	B. Riley	Set Price Target	Buy	$19.00	Low
6/7/2018	B. Riley	Initiated Coverage	Buy	$14.00	Low
5/11/2018	Maxim Group	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $12.00	High
4/30/2018	Maxim Group	Set Price Target	Buy	$9.00	Low
4/2/2018	Maxim Group	Reiterated Rating	Buy	$9.00	High
3/19/2018	Maxim Group	Set Price Target	Buy	$8.00	Low
3/12/2018	Northland Securities	Initiated Coverage	Outperform		High
3/9/2018	Maxim Group	Set Price Target	Buy	$8.00	High
1/4/2018	Maxim Group	Set Price Target	Buy	$8.00	High
11/30/2017	Maxim Group	Upgrade	Buy	$8.00	Low
11/10/2017	Maxim Group	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00	N/A
10/26/2017	Maxim Group	Reiterated Rating	Buy	$7.00	N/A
10/19/2017	Maxim Group	Set Price Target	Buy	$7.00	N/A
9/19/2017	Maxim Group	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00	Low
8/11/2017	Maxim Group	Set Price Target	Buy	$6.00	High
7/31/2017	Maxim Group	Reiterated Rating	Buy	$5.00	Low
7/5/2017	Maxim Group	Reiterated Rating	Buy	$4.00	High
7/5/2017	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$2.62 ➝ $5.00	High
6/14/2017	Maxim Group	Reiterated Rating	Buy	$4.00	Low
5/13/2017	Maxim Group	Set Price Target	Buy	$4.00	Medium
3/10/2017	Maxim Group	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $4.00	High
1/19/2017	Maxim Group	Initiated Coverage	Buy	$3.00	N/A
9/13/2016	Janney Montgomery Scott	Initiated Coverage	Neutral	$2.10	N/A

(Data available from 7/25/2016 forward)

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Today's Range

Now: $46.69

$45.77

$46.89

50 Day Range

MA: $40.02

$30.56

$48.55

52 Week Range

Now: $46.69

$18.20

$49.47

Volume

52,519 shs

Average Volume

277,774 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of BioLife Solutions?

The following equities research analysts have issued research reports on BioLife Solutions in the last year: B. Riley, Benchmark Co., Cowen Inc, KeyCorp, Lake Street Capital, Maxim Group, Northland Securities, Oppenheimer Holdings Inc., Stephens, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for BLFS.

What is the current price target for BioLife Solutions?

8 Wall Street analysts have set twelve-month price targets for BioLife Solutions in the last year. Their average twelve-month price target is $50.38, suggesting a possible upside of 7.9%. B. Riley has the highest price target set, predicting BLFS will reach $61.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $33.00 for BioLife Solutions in the next year.
View the latest price targets for BLFS.

What is the current consensus analyst rating for BioLife Solutions?

BioLife Solutions currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLFS will outperform the market and that investors should add to their positions of BioLife Solutions.
View the latest ratings for BLFS.

What other companies compete with BioLife Solutions?

Other companies that are similar to BioLife Solutions include LivaNova, CONMED, InMode, Outset Medical, ViewRay, Cutera, Natus Medical, TransMedics Group, AxoGen, Semler Scientific, Stereotaxis, Zynex, Edap Tms, Second Sight Medical Products and Movano.

How do I contact BioLife Solutions' investor relations team?

BioLife Solutions' physical mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider's listed phone number is 425-402-1400 and its investor relations email address is [email protected] The official website for BioLife Solutions is www.biolifesolutions.com.